Achilles Therapeutics Shifts Strategy, Seeks Alternatives

Achilles Therapeutics (ACHL) has released an update.

Achilles Therapeutics has halted its TIL-based cNeT therapy development and is closing its CHIRON and THETIS clinical trials, shifting focus to evaluate strategic alternatives, including mergers or sales, with the aid of BofA Securities. The company, with a strong cash position of $95.1 million, is committed to reducing costs and maximizing shareholder value by leveraging its assets and proprietary technology in cancer treatment. Despite the strategic shift, Achilles aims to continue advancing treatments for cancer patients using clonal neoantigen targeting.

For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.